REPLIGEN CORP Payments for (Proceeds from) Other Investing Activities
REPLIGEN CORP (RGEN) reported Payments for (Proceeds from) Other Investing Activities of $416.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsForProceedsFromOtherInvestingActivities · last filed 2026-05-06
- REPLIGEN CORP payments for (proceeds from) other investing activities for the quarter ending 2026-03-31 was $416.00K.
- REPLIGEN CORP payments for (proceeds from) other investing activities for the quarter ending 2025-12-31 was $0.00.
- REPLIGEN CORP payments for (proceeds from) other investing activities for the quarter ending 2025-03-31 was $0.00.
- REPLIGEN CORP payments for (proceeds from) other investing activities for the quarter ending 2024-12-31 was -$1.29M.
- REPLIGEN CORP payments for (proceeds from) other investing activities for fiscal 2025 was $2.40M.
- REPLIGEN CORP payments for (proceeds from) other investing activities for fiscal 2024 was -$1.29M.
- REPLIGEN CORP payments for (proceeds from) other investing activities for fiscal 2023 was -$32.00K.
- REPLIGEN CORP payments for (proceeds from) other investing activities for fiscal 2022 was -$110.00K.
| Period end | Payments for (Proceeds from) Other Investing Activities 3 month | Payments for (Proceeds from) Other Investing Activities 3 month as first filed | Payments for (Proceeds from) Other Investing Activities 6 month | Payments for (Proceeds from) Other Investing Activities 6 month as first filed | Payments for (Proceeds from) Other Investing Activities 9 month | Payments for (Proceeds from) Other Investing Activities 9 month as first filed | Payments for (Proceeds from) Other Investing Activities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | $416.00K 10-Q · filed 2026-05-06 | $416.00K derived: sum of 2 quarters · filed 2026-05-06 | |||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.40M 10-K · filed 2026-02-26 | |||||
| 2025-09-30 | $2.40M 10-Q · filed 2025-11-04 | ||||||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | -$1.29M derived: sum of 2 quarters · filed 2026-05-06 | -$1.28M derived: sum of 3 quarters · filed 2026-05-06 | -$1.28M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | -$1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.28M derived: sum of 2 quarters · filed 2026-02-26 | -$1.28M derived: sum of 3 quarters · filed 2026-02-26 | -$1.29M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $11.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2025-11-04 | $11.00K derived: sum of 2 quarters · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | -$11.00K derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | -$11.00K 10-Q/A · filed 2024-11-18 | -$22.00K derived: sum of 3 quarters · filed 2026-02-26 | -$43.00K derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | -$11.00K 10-Q/A · filed 2024-11-18 | -$22.00K derived: sum of 2 quarters · filed 2026-02-26 | -$43.00K derived: sum of 3 quarters · filed 2026-02-26 | -$43.00K derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | -$11.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-26 | -$32.00K derived: sum of 2 quarters · filed 2026-02-26 | -$32.00K derived: sum of 3 quarters · filed 2026-02-26 | -$32.00K 10-K · filed 2026-02-26 | |||
| 2023-09-30 | -$21.00K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | -$21.00K derived: sum of 2 quarters · filed 2024-11-18 | -$21.00K 10-Q/A · filed 2024-11-18 | -$101.00K derived: sum of 4 quarters · filed 2025-03-14 | |||
| 2023-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $0.00 10-Q/A · filed 2024-11-18 | -$80.00K derived: sum of 3 quarters · filed 2025-03-14 | -$93.00K derived: sum of 4 quarters · filed 2025-03-14 | |||
| 2023-03-31 | $0.00 10-Q/A · filed 2024-11-18 | -$80.00K derived: sum of 2 quarters · filed 2025-03-14 | -$93.00K derived: sum of 3 quarters · filed 2025-03-14 | -$93.00K derived: sum of 4 quarters · filed 2025-03-14 | |||
| 2022-12-31 | -$80.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14 | -$93.00K derived: sum of 2 quarters · filed 2025-03-14 | -$93.00K derived: sum of 3 quarters · filed 2025-03-14 | -$110.00K 10-K · filed 2025-03-14 | |||
| 2022-09-30 | -$13.00K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | -$13.00K derived: sum of 2 quarters · filed 2024-11-18 | -$30.00K 10-Q/A · filed 2024-11-18 | $30.00K 10-Q · filed 2022-11-01 | -$30.00K derived: sum of 4 quarters · filed 2024-11-18 | ||
| 2022-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | -$17.00K 10-Q/A · filed 2024-11-18 | $17.00K 10-Q · filed 2022-08-02 | -$17.00K derived: sum of 3 quarters · filed 2024-11-18 | -$17.00K derived: sum of 4 quarters · filed 2024-11-18 | ||
| 2022-03-31 | -$17.00K 10-Q/A · filed 2024-11-18 | $17.00K 10-Q · filed 2023-05-02 | -$17.00K derived: sum of 2 quarters · filed 2024-11-18 | -$17.00K derived: sum of 3 quarters · filed 2024-11-18 | |||
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | $0.00 derived: sum of 2 quarters · filed 2024-11-18 | $0.00 10-K/A · filed 2024-11-18 | ||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $0.00 10-Q · filed 2022-11-01 | |||||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-02 | ||||||
| 2020-12-31 | $0.00 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |